Skip to main content
SpringerLink
Log in

Opinion and Evidence in Cardiovascular Therapeutics

  • From The World Literature
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Inpharma Weekly provides rapid alerts to news on drugs and drug therapy. Summarizing information selected from over 1 600 biomedical journals, this newsletter is produced by Adis International Limited and is available in a variety of formats. Please contact your nearest Adis office for subscription details.

  2. 95% of patients in the reperfusion therapy group received magnesium sulfate before or concurrently with the initiation of reperfusion.

  3. Costs were those related to inpatient, outpatient and pharmacy services.

  4. Alteplase was administered as a 10mg bolus followed by a 90mg continuous infusion over a period of 2 hours.

  5. In both treatment groups, drug doses were titrated at 2 weeks to meet set targets. At study end, the mean doses for the study drugs were amlodipine 9.5mg, diltiazem 292.9mg, atenolol 89.8mg and isosorbide mononitrate 91.9mg.

  6. The analysis included the Studies of Left Ventricular Dysfunction (SOLVD) Treatment and Prevention trials, the Acute Infarction Ramipril Efficacy (AIRE) trial, the Survival and Ventricular Enlargement (SAVE) trial, the Trandolapril in patients with reduced left ventricular function after acute myocardial infarction (TRACE) trial, and the Heart Outcomes Prevention and Evaluation (HOPE) trial.

  7. Patients who began use of an individual NSAID during follow-up.

  8. Treatment response was defined as a supine DBP of ≤90mm Hg and/or a decrease in supine DBP of ≥10mm Hg.

  9. Costs (2000 values) were those associated with hospitalization, cardiac medications, drug monitoring and cardiac- and complication-related procedures.

  10. The other diuretics group included 527 patients receiving furosemide 40 mg/day. Patients receiving torasemide or furosemide were permitted to take other additional diuretics.

  11. The perindopril/indapamide dosages were 0/1.25, 2/0.625, 2/1.25, 4/0.625, 4/1.25, 4/2.5, 8/1.25, and 8/2.5mg per day.

  12. Major adverse events consisted of death, nonfatal myocardial infarction, and repeat revascularization.

Literature

Literature

  • Sheth T, Parker T, Block A, et al. Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. Am J Cardiol 2002; 90: 496–500

    Article  PubMed  CAS  Google Scholar 

Literature

  • Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting Stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002; 106: 1505–9.

    Article  PubMed  CAS  Google Scholar 

Literature

  • Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) trial: a randomizedd controlled trial. Lancet 2002; 360: 1189–96

    Article  Google Scholar 

Literature

  • Hsu J, Uratsu C, Truman A, et al. Life after a ventricular arrhythmia. Am Heart J 2002; 44: 404–12

    Article  Google Scholar 

Literature

  • Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347: 1143–50

    Article  PubMed  CAS  Google Scholar 

Literature

  • Deanfield JE, Detry J-M, Sellier P, et al. Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial. J Am Coll Cardiol 2002; 40: 917–25

    Article  PubMed  CAS  Google Scholar 

Literature

  • Willems FF, Aengevaeren WRM, Boers GHJ. Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 766–72

    Article  PubMed  CAS  Google Scholar 

Literature

  • Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensinconverting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002; 360: 1037–43

    Article  PubMed  CAS  Google Scholar 

Literature

  • Lonn E, Roccaforte R, Yi Q, et al. Effect of long-term therapy with ramipril in high-risk women. J Am Coll Cardiol 2002; 40: 693–702

    Article  PubMed  CAS  Google Scholar 

Literature

  • Chan AW, Quinn MJ, Bhatt DL, et al. Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. J Am Coll Cardiol 2002; 40: 669–75

    Article  PubMed  Google Scholar 

Literature

  • Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071–3

    Article  PubMed  CAS  Google Scholar 

Literature

  • Kjeldsen SE, Dahlf B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint reduction (LIFE) substudy. JAMA 2002; 288: 1491–8

    Article  PubMed  CAS  Google Scholar 

Literature

  • James IGV, Jones A, Davies P. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Human Hyperten 2002; 16: 605–10

    Article  CAS  Google Scholar 

Literature

  • Bocchi EA, Guimar G, Mocelin A, et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction on congestive heart failure: a double-blind, placebocontrolled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002; 106: 1097–103

    Article  PubMed  Google Scholar 

Literature

  • Berg JM, Kelder JC, Plokker THW, et al. Costs and effectiveness of using coumarins before, during and after coronary angioplasty. Pharmacoeconomics 2002; 20: 847–53

    Article  PubMed  Google Scholar 

Literature

  1. Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672–8

    Article  PubMed  CAS  Google Scholar 

  2. Opie LH, Parving H-H. Diabetic nephropathy: can renoprotection be extrapolated to cardiovascular protection? Circulation 2002; 106: 643–5

    Article  PubMed  Google Scholar 

Literature

  • Cosn J, Dez J, TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Failure 2002; 4: 507–13

    Article  Google Scholar 

Literature

  1. Warlow C. Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke. Stroke 2002 Aug; 2137-8

  2. Diener H-C. Aspirin therapy should be first-line treatment in secondary prevention of stroke - against. Stroke 2002; 33: 2138–9

    Article  PubMed  Google Scholar 

  3. Donnan GA, Davis SM. Aspirin therapy should be first line: probably, but watch this space. Stroke 2002; 33: 2139–40

    Article  PubMed  Google Scholar 

Literature

  • Hussein O, Shneider J, Rosenblat M, et al. Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients. J Cardiovasc Pharmacol 2002; 40: 28–34

    Article  PubMed  CAS  Google Scholar 

Literature

  1. McCullough PA, Sandberg KR, Borzak S, et al. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 2002; 144: 226–32

    Article  PubMed  CAS  Google Scholar 

  2. Reddan DN. Therapy for cardiovascular disease in patients with chronic kidney disease: appropriate caution or the absence of data. Am Heart J 2002; 144: 206–7

    Article  PubMed  Google Scholar 

Literature

  • Dickstein K, Kjekshus J, OPTIMAAL Steering Committee, et al. Effects of losartan and Captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet 2002; 360: 752–60

    Article  PubMed  CAS  Google Scholar 

Literature

  1. Kottke-Marchant K, Bahit MC, Granger CB, et al. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes: the GUSTO-IIb haemostasis substudy. Eur Heart J 2002; 23: 1202–12

    Article  PubMed  CAS  Google Scholar 

  2. Vorchheimer DA, Fuster V. Thrombin inhibitors in acute coronary artery disease. Eur Heart J 2002; 23: 1142–4

    Article  PubMed  CAS  Google Scholar 

Literature

  1. Safar ME, Myers MG, Leenen F, et al. Gender influence on the dose-ranging of a low-dose perindopril-indapamide combination in hypertension: effect on systolic and pulse pressure. J Hypertens 2002; 20: 1653–61

    Article  PubMed  CAS  Google Scholar 

  2. Elliott HL. Gender differences with antihypertensive drug treatment. J Hypertens 2002; 20: 1491–2.

    Article  PubMed  CAS  Google Scholar 

Literature

  1. Zaidat OO, Suarez JI, Santillan C, et al. Response to intra-arterial and combined intravenous and intra-arterial thrombolytic therapy in patients with distal internal carotid artery occlusion. Stroke 2002; 33: 1821–7

    Article  PubMed  CAS  Google Scholar 

  2. Tong DD. Intra-arterial thrombolytic therapy for acute stroke: the debate continues. Stroke 2002; 33: 1827

    PubMed  Google Scholar 

Literature

  • Schnyder G, Roffi M, Flammer Y, et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. JAMA 2002; 288:973–9

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Opinion and Evidence in Cardiovascular Therapeutics. Am J Cordiovosc Drugs 2, 433–443 (2002). https://doi.org/10.2165/00129784-200202060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129784-200202060-00007

Keywords

Search

Navigation